Item 8.01 Other Events.

On September 17, 2020, BeiGene, Ltd. (the "Company" or "BeiGene") announced the first reported data from RATIONALE 304, the Phase 3 trial of its anti-PD-1 antibody tislelizumab in combination with chemotherapy as a potential first-line treatment for patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC), and the first reported data from the pivotal Phase 2 trial of its investigational PARP inhibitor pamiparib in advanced ovarian cancer (OC), at the European Society for Medical Oncology (ESMO) Virtual Congress 2020, which took place on September 19-21. The full text of this press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.



Item 9.01. Exhibits.

(d) Exhibits.
Exhibit No.                                               Description
       99.1               Press release issued by BeiGene, Ltd. on September 17, 2020
       104                The cover page from the Current Report on Form 8-K, formatted in Inline
                          XBRL

--------------------------------------------------------------------------------



                                 Exhibit Index

Exhibit No.               Description
       99.1                 Press release issued by BeiGene, Ltd. on September     17    , 2020
       104                The cover page from this Current Report on Form 8-K, formatted in Inline
                          XBRL

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses